RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO

RXi Pharmaceuticals Corporation RXII, a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology, today announced that it has been granted a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for both the composition and methods of use of RXi's self-delivering (sd-rxRNA®) platform technology. The patent is scheduled to expire in 2029. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO This patent, a continuation of our core sd-rxRNA platform patent, broadly covers the overall structure and modifications of our self-delivering technology in addition to covering an alternative delivery strategy wherein a hydrophobic conjugate is not utilized. "We have been diligent and proactive with our approach to broadly protect our valuable corporate assets," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added, "We are very pleased to receive this notice of allowance from the USPTO for expanded protection of our novel platform. This opens up additional business development and partnering opportunities with our sd-rxRNA platform as we vigorously pursue these initiatives to build shareholder value."